(11:47 GMT) Protagonist Therapeutics Price Target Raised to $145.00/Share From $121.00 by Truist Securities
Dow Jones Newswires
Protagonist Therapeutics Is Maintained at Buy by Truist Securities
- Sources
- Dow Jones Newswires
- Markets
- ETFs, Stocks
- Active symbols
- NASDAQ:PTGX
- Language
- English